BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9539245)

  • 1. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
    Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
    J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
    Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
    Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines.
    Zamboni WC; Houghton PJ; Hulstein JL; Kirstein M; Walsh J; Cheshire PJ; Hanna SK; Danks MK; Stewart CF
    Cancer Chemother Pharmacol; 1999; 43(4):269-76. PubMed ID: 10071976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
    Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGI 114: augmentation of antitumor activity when combined with topotecan.
    Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
    J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
    Houghton PJ; Cheshire PJ; Hallman JC; Gross JL; McRipley RJ; Sun JH; Behrens CH; Dexter DL; Houghton JA
    Cancer Chemother Pharmacol; 1994; 33(4):265-72. PubMed ID: 8281618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
    Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Keshelava N; Groshen S; Reynolds CP
    Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial testing of topotecan by the pediatric preclinical testing program.
    Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB
    Pediatr Blood Cancer; 2010 May; 54(5):707-15. PubMed ID: 20017204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
    Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
    J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
    Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
    Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.